RETAME-PA Trial
Cross-source consensus on RETAME-PA Trial from 1 sources and 5 claims.
1 sources · 5 claims
Evidence quality
Other
Other
Highlighted claims
- The primary endpoint is the proportion of participants with renin unsuppression at 12 months. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
- RETAME-PA is a multicentre, open-label, pragmatic randomised controlled trial in Canada. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
- The trial is a feasibility and proof-of-concept study rather than a trial powered for clinical outcome differences. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
- RETAME-PA randomises participants 1:1 using REDCap with stratification by centre and permuted blocks. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
- The trial is open-label because its arms use different titration strategies, but outcome-related specialists and analysts are blinded to allocation. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial